ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer

NCT03965546 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Liver Cancer
Liver Neoplasms
Metastatic Liver Cancer

Interventions

COMBINATION_PRODUCT: Sorafenib combined with ET140202-T cell
COMBINATION_PRODUCT: TAE combined with ET140202-T cell
BIOLOGICAL: ET140202-T cell

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Collaborators

[object Object]